Memo Therapeutics AG Enters into a Collaboration and Option Agreement with CSL for Development of Recombinant Polyclonal IgG Technology

– Strategic research collaboration to advance MTx’s recombinant polyclonal IgG technology– Agreement includes R&D funding for exploratory work, technology access and, assuming exercise of the option by CSL, a license fee, and development and sales milestones of up to CHF 265 million (USD 328 million)– Provides further validation of MTx’s proprietary DROPZYLLA® technology platform Schlieren […] The post Memo Therapeutics AG Enters into a Collaboration and Option Agreement with CSL for Development of Recombinant Polyclonal IgG Technology first appeared on Memo Therapeutics .